title: Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.
abstract: The rational design of amyloid oligomer inhibitors is yet an unmet drug development need. Previous studies have identified the role of tryptophan in amyloid recognition, association and inhibition. Furthermore, tryptophan was ranked as the residue with highest amyloidogenic propensity. Other studies have demonstrated that quinones, specifically anthraquinones, can serve as aggregation inhibitors probably due to the dipole interaction of the quinonic ring with aromatic recognition sites within the amyloidogenic proteins. Here, using in vitro, in vivo and in silico tools we describe the synthesis and functional characterization of a rationally designed inhibitor of the Alzheimer's disease-associated beta-amyloid. This compound, 1,4-naphthoquinon-2-yl-L-tryptophan (NQTrp), combines the recognition capacities of both quinone and tryptophan moieties and completely inhibited Abeta oligomerization and fibrillization, as well as the cytotoxic effect of Abeta oligomers towards cultured neuronal cell line. Furthermore, when fed to transgenic Alzheimer's disease Drosophila model it prolonged their life span and completely abolished their defective locomotion. Analysis of the brains of these flies showed a significant reduction in oligomeric species of Abeta while immuno-staining of the 3(rd) instar larval brains showed a significant reduction in Abeta accumulation. Computational studies, as well as NMR and CD spectroscopy provide mechanistic insight into the activity of the compound which is most likely mediated by clamping of the aromatic recognition interface in the central segment of Abeta. Our results demonstrate that interfering with the aromatic core of amyloidogenic peptides is a promising approach for inhibiting various pathogenic species associated with amyloidogenic diseases. The compound NQTrp can serve as a lead for developing a new class of disease modifying drugs for Alzheimer's disease.
authors.affiliation: Department of Molecular Microbiology and Biotechnology, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: Roni
authors.initials: R
authors.lastname: Scherzer-Attali
authors.forename: Riccardo
authors.initials: R
authors.lastname: Pellarin
authors.forename: Marino
authors.initials: M
authors.lastname: Convertino
authors.forename: Anat
authors.initials: A
authors.lastname: Frydman-Marom
authors.forename: Nirit
authors.initials: N
authors.lastname: Egoz-Matia
authors.forename: Sivan
authors.initials: S
authors.lastname: Peled
authors.forename: Michal
authors.initials: M
authors.lastname: Levy-Sakin
authors.forename: Deborah E
authors.initials: DE
authors.lastname: Shalev
authors.forename: Amedeo
authors.initials: A
authors.lastname: Caflisch
authors.forename: Ehud
authors.initials: E
authors.lastname: Gazit
authors.forename: Daniel
authors.initials: D
authors.lastname: Segal
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002942:Circular Dichroism; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008954:Models, Biological; D008958:Models, Molecular; D009285:Naphthoquinones / Q000737:chemistry / Q000494:pharmacology*; D010641:Phenotype; D011809:Quinones / Q000737:chemistry / Q000494:pharmacology*; D014364:Tryptophan / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*
chemical_list: C582984:1,4-naphthoquinon-2-yltryptophan; D009285:Naphthoquinones; D011809:Quinones; D014364:Tryptophan